Independent information website. It does not replace a medical examination or advice.
Weight-loss injections

Weight-loss injections: options, benefits and safe access

‘Weight-loss injection’ is a popular search term, not the name of one medicine. It covers several prescription products with different active substances, dosing schedules and approved uses.

Verified sourcesNo medicine salesA doctor decides

In the EU, the principal injectable medicines authorised for weight management include Wegovy, Mounjaro and Saxenda. They influence appetite and satiety, but they are not interchangeable and do not replace nutrition, movement or follow-up care.

What to know

What to know

01

Wegovy contains semaglutide and is normally injected weekly.

02

Mounjaro contains tirzepatide and acts on GIP and GLP‑1 pathways.

03

Saxenda contains liraglutide and is normally injected daily.

What a doctor assesses

What a doctor assesses

A medicine is selected only after an individual medical assessment. BMI is one part of the decision, not the decision itself.

  • BMI, waist circumference and weight history
  • Related conditions and recent test results
  • Current medicines, allergies and contraindications
  • Previous treatment, goals and ability to attend follow-up
Safety and responsible access

Safety and responsible access

Prescription weight-management medicines can cause adverse effects and are not suitable for everyone. The exact risks, dose escalation and monitoring differ by product. Read the current package leaflet and contact a doctor or pharmacist if anything is unclear.

FAQ

Questions about this topic

Which weight-loss injection is best?+

There is no universally best product. The choice depends on indication, health history, contraindications, tolerance, availability and the clinician’s judgement.

Can I decide from this page whether the treatment is suitable for me?+

No. This page is educational. A licensed doctor must consider your history, other medicines, contraindications and local product information.

Official sources

Official sources

EMA · GLP-1 shortages and authorised usesOpen official informationEuropean Medicines AgencyOpen official informationYour Europe · cross-border prescriptionsOpen official information

Sources reviewed 12 August 2026.